{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:56:45Z","timestamp":1761897405385,"version":"3.41.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the clinical course of patients with neovascular age-related macular degeneration (nAMD) after developing endophthalmitis during their treatment with intravitreal injections.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Multicenter, retrospective series.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>From April 2013 to October 2018, 196,598 intravitreal anti\u2013vascular endothelial growth factor (VEGF) injections were performed, with 75 cases of endophthalmitis (incidence 0.0381%). There was no association between intravitreal anti-VEGF drug (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.29), anesthetic method (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.26), povidone concentration (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.22), or any intraprocedure variable and endophthalmitis incidence. Seventy-two patients (96%) were treated with intravitreal tap and inject , while 3 underwent immediate pars plana vitrectomy. After endophthalmitis resolution, 17 patients (22.7%) were not re-treated for nAMD (in 10 cases due to inactive disease; follow-up, 115 \u00b1 8.4 weeks). Patients required less frequent anti-VEGF injections after infection (7.4 \u00b1 0.61 weeks vs. 11.5 \u00b1 1.8 weeks; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.004). Preinfection logarithm of the minimum angle of resolution visual acuity was 0.585 \u00b1 0.053 (\u223c20\/77). It worsened with endophthalmitis (1.67 \u00b1 0.08, \u223c20\/935; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and again on postendophthalmitis treatment day 1 (1.94 \u00b1 0.064; count fingers; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), but improved after reinitiating nAMD therapy (1.02 \u00b1 0.11; \u223c20\/209; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). Better visual acuity on postendophthalmitis week 1 (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002) and reinitiation of nAMD treatment (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.008) were associated with better final visual acuity, and streptococcal culture with worse visual acuity (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.028). The postendophthalmitis treatment interval was associated with the anti-VEGF drug used (aflibercept = ranibizumab &gt; bevacizumab; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Patients with nAMD required fewer injections after endophthalmitis, suggesting a biological change in disease activity. Neovascular age-related macular degeneration became quiescent in 13.3% of eyes. Most achieved better outcomes with anti-VEGF reinitiation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002998","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T18:15:06Z","timestamp":1603390506000},"page":"1242-1250","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["CLINICAL OUTCOMES AND TREATMENT COURSE OF EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION FOLLOWING THE DEVELOPMENT OF ENDOPHTHALMITIS"],"prefix":"10.1097","volume":"41","author":[{"given":"Nicole","family":"Koulisis","sequence":"first","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"},{"name":"Department of Ophthalmology, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros N.","family":"Moysidis","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"},{"name":"The Retina Partners, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viren K.","family":"Govindaraju","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne Merrylees","family":"Dersch","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Capone","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J.","family":"Covert","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajir","family":"Dadgostar","sequence":"additional","affiliation":[{"name":"The Retina Partners, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Bawa","family":"Dass","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly A.","family":"Drenser","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert E.","family":"Engstrom","sequence":"additional","affiliation":[{"name":"The Retina Partners, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa J.","family":"Faia","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce R.","family":"Garretson","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir H.","family":"Guerami","sequence":"additional","affiliation":[{"name":"The Retina Partners, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Hanscom","sequence":"additional","affiliation":[{"name":"The Retina Partners, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamer H.","family":"Mahmoud","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan R.","family":"Margherio","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kean T.","family":"Oh","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Randhawa","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul V.","family":"Raphaelian","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Rhoades","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan J.","family":"Ruby","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian J.","family":"Sanfilippo","sequence":"additional","affiliation":[{"name":"The Retina Partners, Los Angeles, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott R.","family":"Sneed","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael T.","family":"Trese","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy D.","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George A.","family":"Williams","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Yedavally","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek S.","family":"Hassan","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, PC., Department of Ophthalmology, Oakland University William Beaumont School of Medicine, Royal Oak, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s40662-016-0063-5","article-title":"Epidemiology of age-related macular degeneration (AMD): associations with cardiovascular disease phenotypes and lipid factors","volume":"3","author":"Pennington","year":"2016","journal-title":"Eye Vis (Lond)"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Group","year":"2011","journal-title":"N Engl J Med"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ophtha.2017.10.010","article-title":"Real-world vision in age-related macular degeneration patients treated with single anti-VEGF drug type for 1 Year in the IRIS registry","volume":"125","author":"Rao","year":"2018","journal-title":"Ophthalmology"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ophtha.2018.08.035","article-title":"Macular morphology and visual acuity in year five of the comparison of age-related macular degeneration treatments trials","volume":"126","author":"Jaffe","year":"2019","journal-title":"Ophthalmology"},{"key":"R8-20250607","first-page":"1053","article-title":"Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab","volume":"10","author":"Nudleman","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian treat and extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: 1-year results of the randomized CANTREAT study","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ajo.2019.01.005","article-title":"Extended (\u2265q12 Weeks) dosing interval with intravitreal aflibercept and ranibizumab in neovascular AMD: post hoc analysis of VIEW trials","volume":"200","author":"Khurana","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ajo.2018.05.026","article-title":"The treat-and-extend injection regimen versus alternate dosing strategies in age-related macular degeneration: a systematic review and meta-analysis","volume":"192","author":"Okada","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.oret.2017.10.003","article-title":"Baseline predictors for five-year visual acuity outcomes in the comparison of AMD treatment trials","volume":"2","author":"Ying","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2018.06.022","article-title":"Endophthalmitis rates after bilateral same-day intravitreal anti-vascular endothelial growth factor injections","volume":"194","author":"Borkar","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.2147\/OPTH.S169143","article-title":"Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis","volume":"12","author":"Kiss","year":"2018","journal-title":"Clin Ophthalmol"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/archopht.1995.01100120009001","article-title":"A randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Endophthalmitis Vitrectomy Study Group","volume":"113","year":"1995","journal-title":"Arch Ophthalmol"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ophtha.2013.08.037","article-title":"The role of topical antibiotic prophylaxis to prevent endophthalmitis after intravitreal injection","volume":"121","author":"Storey","year":"2014","journal-title":"Ophthalmology"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/ICB.0000000000000352","article-title":"Resolution of treatment-resistant subretinal fluid in a patient with exudative age-related macular degeneration following endophthalmitis","volume":"11","author":"Kally","year":"2017","journal-title":"Retin Cases Brief Rep"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1136\/bjophthalmol-2017-311055","article-title":"Outcome of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration in real-life setting","volume":"102","author":"Kataja","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.ophtha.2014.10.027","article-title":"Postinjection endophthalmitis in the comparison of age-related macular degeneration treatments trials (CATT)","volume":"122","author":"Meredith","year":"2015","journal-title":"Ophthalmology"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1097\/IAE.0000000000002300","article-title":"Long-term visual outcomes and clinical features after anti-vascular endothelial growth factor injection-related endophthalmitis","volume":"39","author":"Rayess","year":"2019","journal-title":"Retina"},{"key":"R22-20250607","first-page":"1097","article-title":"Relative quiescence of exudative age-related macular degeneration after resolution of postinjection endophthalmitis","volume":"10","author":"Arnett","year":"2019","journal-title":"Retina"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.oret.2018.09.013","article-title":"Predictors of endophthalmitis after intravitreal injection: a multivariable analysis based on injection protocol and povidone iodine strength","volume":"3","author":"Stem","year":"2019","journal-title":"Ophthalmol Retina"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.preteyeres.2010.09.003","article-title":"Metabolic physiology in age related macular degeneration","volume":"30","author":"Stefansson","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.preteyeres.2014.03.002","article-title":"Cholesterol in the retina: the best is yet to come","volume":"41","author":"Pikuleva","year":"2014","journal-title":"Prog Retin Eye Res"},{"key":"R26-20250607","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1194\/jlr.R010538","article-title":"The ins and outs of cholesterol in the vertebrate retina","volume":"51","author":"Fliesler","year":"2010","journal-title":"J Lipid Res"},{"key":"R27-20250607","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1038\/ng.3448","article-title":"A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants","volume":"48","author":"Fritsche","year":"2016","journal-title":"Nat Genet"},{"key":"R28-20250607","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/eye.2015.203","article-title":"Complement pathway biomarkers and age-related macular degeneration","volume":"30","author":"Gemenetzi","year":"2016","journal-title":"Eye (Lond)."},{"key":"R29-20250607","doi-asserted-by":"crossref","first-page":"546786","DOI":"10.1155\/2012\/546786","article-title":"Mechanism of inflammation in age-related macular degeneration","volume":"2012","author":"Parmeggiani","year":"2012","journal-title":"Mediators Inflamm"},{"key":"R30-20250607","doi-asserted-by":"crossref","first-page":"768026","DOI":"10.1155\/2014\/768026","article-title":"Oxidative stress, hypoxia, and autophagy in the neovascular processes of age-related macular degeneration","volume":"2014","author":"Blasiak","year":"2014","journal-title":"Biomed Res Int"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002998","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:04:19Z","timestamp":1749319459000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000002998"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002998","relation":{},"ISSN":["0275-004X"],"issn-type":[{"type":"print","value":"0275-004X"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}